Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-rhAnnexin V-128 Imaging in Spondyloarthritis
NCT03232580Phase 2Terminated
- Sponsor
- Advanced Accelerator Applications
- Start
- Sep 2017
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of technetium-tc99m-labeled annexin a5 in spondyloarthritis (SpA), sponsored by Advanced Accelerator Applications. Primary endpoints: 99mTc-rhAnnexin V-128 Uptake and 99mTc-rhAnnexin V-128 Uptake Adjudication. Started Sep 2017; status: terminated.
02
Drugs
technetium-tc99m-labeled annexin a5
03
Conditions
spondyloarthritis (SpA)
Beyond the preview
Go deeper on NCT03232580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232580.